Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors, as well as ProTmune for the treatment of hematologic malignancies and rare genetic disorders. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: fatetherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | Buy | Jefferies | |
| 10/31/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 10/27/2025 | $7.00 | Neutral → Outperform | Wedbush |
| 11/18/2024 | Underperform → Neutral | BofA Securities | |
| 6/17/2024 | $4.00 → $6.00 | Neutral → Overweight | Piper Sandler |
| 3/27/2023 | $6.00 | Equal Weight | Wells Fargo |
| 1/24/2023 | $115.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 1/6/2023 | $20.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/6/2023 | $71.00 → $12.00 | Overweight → Neutral | Piper Sandler |
| 1/6/2023 | Outperform → Market Perform | Cowen |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Jefferies resumed coverage of Fate Therapeutics with a rating of Buy
H.C. Wainwright upgraded Fate Therapeutics from Neutral to Buy and set a new price target of $5.00
Wedbush upgraded Fate Therapeutics from Neutral to Outperform and set a new price target of $7.00
BofA Securities upgraded Fate Therapeutics from Underperform to Neutral
Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously
Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00
H.C. Wainwright downgraded Fate Therapeutics from Buy to Neutral and set a new price target of $7.00 from $115.00 previously
BMO Capital Markets downgraded Fate Therapeutics from Outperform to Market Perform and set a new price target of $7.00 from $20.00 previously
Piper Sandler downgraded Fate Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $71.00 previously
Cowen downgraded Fate Therapeutics from Outperform to Market Perform
10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
DEFA14A - FATE THERAPEUTICS INC (0001434316) (Filer)
DEF 14A - FATE THERAPEUTICS INC (0001434316) (Filer)
SCHEDULE 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SCHEDULE 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
10-K - FATE THERAPEUTICS INC (0001434316) (Filer)
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
144 - FATE THERAPEUTICS INC (0001434316) (Subject)
10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4/A - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
Fastest customizable press release news feed in the world
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on June 1, 2026, the Company granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees
FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique ability to traffic to tumor site and functionally persist without the reliance on conditioning chemotherapy in allogeneic patient setting SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, presented clinical data this weeken
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026. Presentation details are as follows: ASCO – American Society of Cancer Oncology Product Candidate: FT836 Title: Prelim
Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectorsNEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue fun
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
Market News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 FDA selects FT819 into the CDRP (CMC Development and Readiness Pilot) program enabling early and enhanced communication with the FDA to ensure CMC readiness for accelerated clinical timelines Clinical data presented at Pediatric Rheumatology Symposium 2026 and Congress of Clinical Rheumatology – East 2026 highlights safety and efficacy of single dose of FT819 with reduced conditioning in SLE Preclinical data presented at the American Association for Cancer Research
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following treatment with B cell shift towards less class-switched BCR repertoire Preclinical data for FT839 demonstrate comprehensive targeting of multicellular disease across autoimmune and hematological malignancies; data shows broad and selective depletion of pathogenic immune cell subtypes in rheumatoid arthritis and systemic lupus erythematosus disease without the use of conditioning chemotherapy Preclinical data for FT836 shows effective elimination of broad
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation provide opportunity for expedited regulatory pathway and advancement of FT819 Phase 2 potentially registrational clinical trial in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pi
This live feed shows all institutional transactions in real time.
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)
Live Leadership Updates
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experience in the life sciences industry, including over 10 years serving as CFO across innovative life science companies, with deep domain expertise in autoimmune diseases, including lupus. "We are excited to wel
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza
- Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million - Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein coupled receptor biology - Radionetics expands board of directors with the appointment of Eric Shiozaki, Ph.D., Partner at DCVC Bio Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new invest
SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the Global Commercial CAR T lead at Celgene Corporation where he oversaw the commercial development strategy of the company's CAR T-cell therapies. "We are excited to welcome Brian to Fate Therapeutics as we begin to chart our late-stage clinical developme
> Dr. Agarwal is Currently Chairwoman of Onxeo's Board, a Position Held Since June 2021 > Company Outlines Development Strategy Plans Including Preparation for U.S. Pre-IND Meeting for First-in-Class DDR Inhibitor AsiDNA® and Plans for Building Infrastructure in the United States > New Private Financing Expands Onxeo's Runway Into Second Quarter 2023 Regulatory News: Onxeo S.A. (PARIS:ALONX, Nasdaq First North Copenhagen: ONXEO))), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the appointment of Dr. Shefali Agarwal as President and Chief Executive O
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biopharmaceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel (cilta-cel) from proof-of-concept in 2018 to BLA pr
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cGMP manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. As Chief Technical Officer, Mark will oversee the Company's manufacturing, technical, and supply chain operations. "We ar
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 years with the Company. Dr. Shoemaker has been with Fate Therapeutics since February 2009, having served as the Company’s Chief Scientific Officer since May 2015. Bob Valamehr, Ph.D., Chief Research and Development Officer of Fate Therapeutics and scientific leader of its iPSC Product Platform since January 2010, w
Live finance-specific insights
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under
Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy IND Application Cleared by FDA for FT825/ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 iPSC-derived CAR T-cell Product Platform Expanded into Autoimmunity; IND Application Cleared by FDA for FT819 CD19-targeted 1XX CAR T-cell Program for Systemic Lupus Erythematosus $350 Million in Cash, Cash Equivalents, and Investments to Support Runway into 2H25 SAN DIEGO, Nov. 08, 2023 (GLOBE N
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Pre
Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy 2H23 IND Submission Planned under ONO Collaboration for FT825/ONO-8250; HER2-targeted CAR T-cell Program Incorporates Seven Novel Synthetic Controls Designed to Overcome Unique Challenges in Treating Solid Tumors Dose Escalation Ongoing in Phase 1 Studies of FT819 CD19-targeted 1XX CAR T-cell Program for B-cell Malignancies and of FT576 BCMA-targeted CAR NK Cell Program for Multiple Myeloma Ended 2Q23 with $385 Million in Cash, Cash Equivalents, and Investments Supporting Runway in
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Pres
Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma FT576 BCMA-targeted CAR NK Cell Program Accruing Patients in Multi-dose Escalation Cohorts for Multiple Myeloma; Initial Translational Data Support Potential of Combination Regimen to Induce Differentiated Immune Reconstitution Profile and Extend FT576 Functional Persistence Clinical Initiation of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma Anticipated in 2H23; Preclinical Studies Ongoing to Extend Clinical Reach to Autoimmune Diseases Completed Corp
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Present